Medicaid GLP-1 coverage in Connecticut, 2026.

HUSKY Health (Connecticut Medicaid) does not cover Wegovy for weight loss.

Connecticut last reviewed its drug list in 2025-12.

Most state Medicaid programs still exclude weight-loss-indication GLP-1, but the diabetes path is covered nearly everywhere with prior authorization (your doctor asks the plan to approve it first).

Coverage summary

IndicationCoverage
Wegovy (weight loss)No
Zepbound (weight loss)Limited
Ozempic / Mounjaro (type 2 diabetes)Yes
Compounded semaglutide / tirzepatideNo

If Connecticut Medicaid will not cover it, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health

A clinical trial costs nothing, and nobody checks your income.

Prior-authorization criteria

These rules come from the state preferred drug list (PDL), the list of drugs Connecticut Medicaid has agreed to pay for.

CriterionValue
PA burdenMedium
BMI threshold (weight-loss path)The state does not publish one. Ask your plan.
Comorbidity requiredNo
Last PDL update reviewed2025-12

What this means in practice

Connecticut Medicaid (HUSKY Health) does not cover GLP-1s for weight loss on its own. It does cover them for four other reasons. Wegovy is covered to cut heart attack and stroke risk, and for MASH, a fatty liver disease. Zepbound is covered for moderate to severe sleep apnea, which means your sleep study scored 15 or higher and you are already on a CPAP machine. That one has been in place since July 1, 2025. Type 2 diabetes is the fourth route. All four need your doctor to get approval first. That is the prior authorization step.

Managed-care organizations in Connecticut

Connecticut Medicaid operates primarily as fee-for-service. PA submissions go directly to the state Medicaid pharmacy benefit administrator rather than to a contracted managed-care organization (MCO), the kind of private health plan that runs Medicaid coverage in most states.

Cash-pay alternatives if Medicaid does not cover you

Connecticut's Medicaid weight-loss drug benefit covers orlistat, Xenical and phentermine at a BMI above 40, or above 35 with a diagnosed comorbid condition. No GLP-1 is on that list. Type 2 diabetes on your chart still opens the diabetes route.

If you end up paying cash, the GLP-1 cost guide has what each cash route costs, from the compounded floor to the manufacturer-direct brand prices. For ranked cash-pay options, see programs ranked by price and programs under $150 a month. Manufacturer savings cards and patient-assistance programs are not routes here: federal law bars the cards for anyone on Medicaid, and the free-drug programs require being uninsured.

If a supply gap rather than cost is blocking your refill, the GLP-1 shortage tracker shows which formulations the FDA lists as in shortage now. And if you are 65 or older and also have Medicare, the senior GLP-1 hub lays out the Medicare coverage paths for dual-eligible patients.

For the full cash-pay picture specific to Connecticut, see the cheapest GLP-1 in Connecticut guide.

12 GLP-1 clinical trials are recruiting in Connecticut, and a study supplies its own study medication. Every site is listed on GLP-1 clinical trials in Connecticut.

Take it to your prescriber: PA letter library

If you qualify under one of the covered uses above, prior authorization is the cheapest path.

We keep a PA letter library with templates for 13 health plans, Anthem BCBS, Kaiser, Humana, Tricare and FEHB among them, sorted by the 7 clinical pictures that qualify. Each one cites the plan's own policy document, the diagnosis codes it asks for and the clinical trial evidence behind them.

If you have type 2 diabetes plus kidney disease and heart disease, that combination is the strongest case for approval in any state, and the templates cite the three clinical trials behind it.

If your PA is denied, the appeal letter library has denial-specific templates. For the commercial and Medicare coverage paths, see the GLP-1 insurance guide.

Connecticut Medicaid GLP-1 FAQ

Does HUSKY Health (Connecticut Medicaid) cover Wegovy for weight loss?
No. Connecticut Medicaid does not cover Wegovy for the weight-loss indication as of the 2025-12 preferred drug list review. If you have type 2 diabetes, the diabetes-indicated GLP-1s (Ozempic, Mounjaro) may still be covered with prior authorization.
Does HUSKY Health (Connecticut Medicaid) cover Zepbound for weight loss?
It depends. Coverage of Zepbound for weight loss under Connecticut Medicaid is limited and can vary by managed-care plan. Prior authorization is required. Check your specific plan's drug list. Last state review: 2025-12.
Does HUSKY Health (Connecticut Medicaid) cover Ozempic or Mounjaro for diabetes?
Yes. Connecticut Medicaid covers Ozempic and Mounjaro for type 2 diabetes with prior authorization, usually after a trial of metformin. The diabetes pathway does not carry the BMI threshold that applies to the weight-loss pathway.
What if HUSKY Health (Connecticut Medicaid) does not cover my GLP-1?
If your GLP-1 is not covered, the routes left do not run through Medicaid. A clinical trial costs nothing and many pay you for your time. Nobody checks your income. Manufacturer savings cards are not a route here, because federal law bars them for anyone on Medicaid. The cheapest route left is cash-pay compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy or Ozempic. The prices checked August 31, 2026 are on the chart. Connecticut's Medicaid weight-loss drug benefit covers orlistat, Xenical and phentermine at a BMI above 40, or above 35 with a diagnosed comorbid condition. No GLP-1 is on that list. Type 2 diabetes on your chart still opens the diabetes route. If you were denied, the appeal letter library has denial-specific templates.

Other state Medicaid pages

See the full 51-state coverage table for the side-by-side view across every US state.

How we built this page

Compiled from each state Medicaid's published preferred drug list, PA criteria and PDL committee minutes. State Medicaid programs are not federally required to cover obesity drugs; the diabetes indication is covered nearly everywhere with PA. State-level data is point-in-time and shifts each PDL cycle. Always verify with your state Medicaid plan before relying on this page.

Last updated: 2026-08-28. We check each state Medicaid PDL and PA criteria quarterly. If you have recently had a different experience with Connecticut Medicaid, email hello@glpchart.com with the details and we will check it.

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.